The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology-related, in any country.
AUM (million)
USD 1,630.00
FSM Risk Rating
10 - Highest Risk
Launch Date
09 Dec 2018
Launch Price
USD 10.00
Historical Dividend
-
Dividend Yield (%)
-
Dividend Frequency
-
CPF Risk Classification
na
Min. Initial Amount
SGD 1,346.10 / USD 1,000.00
Min. RSP Investment
SGD 200.00
RSP Special List
Yes
Annual Expense Ratio
5.19%
LEARN MORE
Latest NAV Price
Past 3 Months
USD 37.05
USD 1.26
More
Annualised Returns
1 WK 3.140%
1 MTH -1.450%
3 MTH 3.290%
6 MTH 1.720%
YTD 2.200%
1 YR 55.980%
2 YR 21.760%
3 YR 19.920%
5 YR 12.920%
10 YR 0.000%
Calendar Year Returns
2025 49.375%
2024 6.059%
2023 23.282%
2022 -3.778%
2021 -5.174%
Fund Historical Price
1Y High
38.81
19 Apr 2026
1Y Low
22.81
30 Jun 2025
3Y High
38.81
19 Apr 2026
3Y Low
17.55
31 Oct 2023
All Time High
38.81
19 Apr 2026
All Time Low
8.51
23 Dec 2018
Documents
Prospectus
31 May 2026
Semi-Annual Report
27 Feb 2026
Annual Report
31 Oct 2025
Product Highlights Sheet
03 Oct 2025
Fund Factsheet
24 May 2026
Funds Objective and Investment Information
Asset Class
Equity
Sector
Biotechnology
Geographical Allocation
Global
RSP Special List
Yes
MAS Registration
Recognised
Right to cancel
No
Pricing Basis
Forward Pricing
Min. Initial Amount
SGD 1,346.10 / USD 1,000.00
Min. Subsequent Investment
SGD 134.61 / USD 100.00
Min. Redemption Amount
USD 100.00
Min. RSP Investment
SGD 200.00
Min. Holdings
USD 1,000.00
Charges & Fees
Yes
Dividend
No
Fund Manager Information
Janus Henderson Investors is a global asset manager offering a full suite of actively managed investment products across asset classes. Established through the merger of Janus Capital and Henderson in 2017, our rich history as independent investment managers stretches back to 1934.
From our origins in bottom-up, analysis-based strategies with a strong research-based approach to security selection, Janus Henderson today offers active management across equities, fixed income, alternatives and multi-asset strategies. We believe the notion of ‘connecting’ is powerful – it has shaped our evolution and our world today.
At Janus Henderson, we seek to benefit clients through the connections we make. Connections enable strong relationships based on trust and insight as well as the flow of ideas among our investment teams and our engagement with companies. These connections are central to our values, to what active management stands for and to the long-term outperformance we seek to deliver.
Janus Henderson has more than 340 investment professionals, expertise across all major asset classes and clients spanning the globe, entrusting us with more than US$405.1bn.
Source: Janus Henderson Investors. Staff and AUM data as at 31 March 2021. AUM data excludes Exchange-Traded Note (‘ETN’) assets.
READ MORE
Company
Janus Henderson Investors - Horizon Fund SICAV
Address
138 Market Street #34-03/04 CapitaGreen Singapore 048946
Fund Top 10 Holdings (40.72% of Total Assets
22 May 2026)
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
Name
Weighting (%)
Sector
Praxis Precision Medicines
6.39
-
Revolution Medicines
4.59
-
Bridgebio Pharma
4.34
-
Argenx
3.98
-
Vertex Pharmaceuticals
3.81
-
United Therapeutics
3.80
-
Gilead Sciences
3.77
-
Mirum Pharmaceuticals
3.43
-
PTC Therapeutics
3.31
-
Regeneron Pharmaceuticals
3.30
-
Country/Region
Last Updated on 22 May 2026
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
United States (US)
86.92%
Belgium
4.03%
Denmark
3.12%
United Kingdom
3.00%
France
1.84%
Canada
0.87%
Sector
Last Updated on 22 May 2026
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
Biotechnology
87.11%
Pharmaceuticals
11.71%
Health Care Equipment
0.93%
Health Care Services
0.01%
Payment Method
Included under Cash Yes
Included under SRS Yes
Included under CPFIS-OA No
Included under CPFIS-SA No
Buy Processing Flow
Order Placement
17 Jun 2026
Order Transact
17 Jun 2026
Complete to Holdings
23 Jun 2026
Sell Processing Flow
Order Placement
17 Jun 2026
Order Transact
17 Jun 2026
Paid Out
26 Jun 2026
Risk Metric
3 YR Annualised Volatility
24.78%
3 YR Sharpe Ratio
0.77
1 YR Max Drawdown -9.49%
3 YR Max Drawdown -35.89%
Upcoming Fund Holidays MORE
Singapore
There are no upcoming fund holidays for this fund.
Fund Holiday
22Jun
Fund Holiday
Tools
Fund Ideas
Fund Returns
Fund RSP
Fund Selector
Recommended Fund
Related Articles
FUNDS Funds in Focus – May 2024
Hu You
10 Jun 2024 | 2327 views
FUNDS Q&A Series: Capitalising on Healthcare's Growing Demands with This Biotech Fund
iFAST Research Team
21 May 2024 | 1701 views
FUNDS New Funds on Board – [1Q24]
Hu You
22 Apr 2024 | 1566 views
For further assistance, please call our hotline at 6557 2853 from:
8:30am to 10:30pm, (Mondays to Fridays except PH) and
8:30am to 12:30pm, (Saturdays except PH)
@ 2026. All Rights Reserved. Reg. No. 200000231R S&P ratings, @ 2026, S&P Capital IQ (and its affiliates, as applicable). All Rights Reserved. Copyright @ 2026, American Bankers Association CUSIP Database provided by the S&P Capital IQ LLC. All rights reserved. Copyright @ 2026, Market data provided by Cboe One Real-Time Quote, Morningstar Research Pte. Ltd. & Morningstar Real-Time Data Ltd. All Rights Reserved. Copyright @ 2026, HKEX market data provided by HKEX Information Services Ltd. All Rights Reserved.
We use cookies
If you close this message or continue to use this site, you will consent to the use of Cookies, unless you choose to disable them. Click on our Privacy Policy to understand more.